Difference between revisions of "Gefitinib (Iressa)"
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor(TKI). Activating mutations of EGFR can drive tumor growth by activating pathways that promote proliferation, invasion, angiogenesis, metastasis, and inhibition of cell death. Gefitinib binds to the EGFR tyrosine kinase domain and inhibits these over-active signalling pathways. There are differences between specific EGFR mutations and their likelihood of clinical response to EGFR TKIs.<ref name="insert">[http://www.astrazeneca.ca/documents/ProductPortfolio/IRESSA_PM_en.pdf Gefitinib (Iressa) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/gefitinib.pdf Gefitinib (Iressa) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Activating mutations of EGFR can drive tumor growth by activating pathways that promote proliferation, invasion, angiogenesis, metastasis, and inhibition of cell death. Gefitinib binds to the EGFR tyrosine kinase domain and inhibits these over-active signalling pathways. There are differences between specific EGFR mutations and their likelihood of clinical response to EGFR TKIs.<ref name="insert">[http://www.astrazeneca.ca/documents/ProductPortfolio/IRESSA_PM_en.pdf Gefitinib (Iressa) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/gefitinib.pdf Gefitinib (Iressa) package insert (locally hosted backup)]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 02:36, 21 January 2012
General information
Class/mechanism: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Activating mutations of EGFR can drive tumor growth by activating pathways that promote proliferation, invasion, angiogenesis, metastasis, and inhibition of cell death. Gefitinib binds to the EGFR tyrosine kinase domain and inhibits these over-active signalling pathways. There are differences between specific EGFR mutations and their likelihood of clinical response to EGFR TKIs.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Gefitinib (Iressa) patient drug information (Chemocare)[3]
- Gefitinib (Iressa) patient drug information (UpToDate)[4]